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units. The AIR increased seromucoids to 95.1±5.7 vs 8.4±1.6mg/dl
in controls (p< 0.05). The AIR reduced CYP3A6 activity to 5972±464,
5415±541 and 2639±747, and CYP1A2 activity, 3026±113, 3856±1151,
3805±753 for control, 20 and 30 days of CS, respectively (p< 0.05
compared without AIR). CS did not affect NADPH activity or expression.
Conclusions: It is concluded that CS does not affect activity or expres-
sion of CYP3A6 and CYP1A2, nor prevents AIR-induced down-regulation.
These results are in agreement with the absence of CS-drug interactions
in humans.
534 SIX-MONTH EFFICACY OF INTRA-ARTICULAR HYALURONIC
ACID FOR CARPOMETACARPAL JOINT OSTEOARTHRITIS
M. Massarotti, F. Uboldi, E. Valcamonica, L. Belloli, B. Marasini.
Rheumatology Unit, IRCCS Humanitas Clinical Institute, University of
Milan, Rozzano (Milan), ITALY
Purpose: To investigate the six-month efﬁcacy of a three intra-articular
hyaluronic acid (HA) injection course on pain relief in osteoarthritis (OA)
of the carpometacarpal joint (CMC).
Methods: Thirty-nine female patients affected by symptomatic CMC OA
(aged 66±8 years, mean±SD) were treated with three once-weekly intra-
articular injections of HA (Hyalgan 1ml). All subjects met ACR criteria
for hand OA and had CMC OA grade 1−4 according to Kellgren and
Lawrence on standard X-ray performed within 6 months before the
inclusion. Fifty-nine CMC joints were treated and evaluated (twenty-three
patients underwent to bilateral injections, thirteen patients had only one
hand treated). Patients were followed for a 6-month period after the last
injection. Treatment efﬁcacy was assessed through visual analogue scale
(VAS) pain quantiﬁcation (baseline; 2nd and 3rd injection; one, three and
six months after the last injection). Side effects were recorded.
Results: VAS was signiﬁcantly reduced after the ﬁrst injection (2nd
injection vs baseline, p< 0.01; 3rd injection vs baseline, p< 0.0001;
3rd injection vs 2nd injection, p< 0.05) and reached the slowest score
one month after the last injection. The efﬁcacy was maintained for all
the 6-month follow-up period (one month vs baseline, p< 0.0001;three
months vs baseline, p< 0.0001; six months vs baseline, p = 0.0001 – one
month vs 3rd injection, p = n.s.;three months vs 3rd injection, p = n.s.; six
months vs 3rd injection, p = n.s.). Only minor side effects were observed
(mild pain and/or ecchymosis in injection site).
Conclusions: Our study supports viscosupplementation with HA as a
safe and efﬁcacious approach for symptomatic CMC OA. Our schedule
based on three weekly intra-articular injections supplies pain relief lasting
as long as 6 months with negligible side-effects.
Further studies are needed to determine the long-term efﬁcacy and the
optimal treatment schedule.
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Purpose: Recently extensive evidence based recommendations have
been made in the Netherlands for diagnosis and treatment of knee and hip
osteoarthritis (OA). Based on this a three months standardized treatment
protocol was developed including education, advice about weight loss
and lifestyle measures, use of analgetics, referral for physical therapy
and when necessary other interventions like intra-articular injections. To
implement this protocol an outpatient clinic was initiated for conservative
treatment of primary osteoarthritis of the knee. The aim of this study was
to assess the results of a standardized conservative treatment protocol
for knee OA.
Methods: Patients with symptomatic clinical knee OA according to the
ACR classiﬁcation criteria referred to the rheumatology department by
general practitioners were treated at the outpatient clinic of the Sint
Maartenskliniek. In addition to patient education, treatment consisted of
three main modalities: stepwise analgesia, referral to exercise therapy
using ‘graded activity principle’ and weight reduction advises if necessary.
Visits took place at the outpatient clinic at intake and after 12 weeks;
patients were contacted by telephone at 4 and 8 weeks. Pain and ADL
function were measured using a Likert scale (0−10) for pain and patient
global assessment (PGA) and using WOMAC compatible subscales of
the Knee injury and Osteoarthritis Outcome Score (WKOOS) (Likert
scale version). WKOOS based OMERACT-OARSI responder criteria were
measured in all patients after twelve weeks. Finally kinesiophobia was
measured using the Tampa Scale of Kinesiophobia (TSK).
Results: Fifteen patients (13 females, mean age (±SD) 62±12) were
thus far included. At intake the following values were found (mean±SD):
pain and PGA 6.1±1.9 and 6.1±2.5 respectively, WOMAC compatible
subscales for pain, stiffness and function 11±4.4, 4.5±1.5 and 38±14
respectively, BMI 34.4±4.8 and TSK scores 40±6 (cut-off for irrational
kinesiophobia >37). After twelve weeks pain, PGA, BMI and TSK did
not change signiﬁcantly: scores were 6.4±3.2 (p = 0.8), 6.2±2.7 (p = 0.9),
33.7±5.0 (p = 0.09) and 39±5 (p = 0.3) respectively. WKOOS based
OMERACT-OARSI responder criteria were however met in 40% of the
patients.
Conclusions: Although 40% of patients met the OMERACT-OARSI re-
sponder criteria using this protocol, mean pain and ADL function did not
change, indicating that a subgroup of patient worsened. However, this
sample probably reﬂects a highly selected population. Future research
should be directed at identifying prognostic factors for non-response such
as body weight and kinesiophobia.
536 EFFECTS OF EXOGENOUSLY INJECTED HYALURONAN ON
THE ARTICULAR CARTILAGE IN A RAT IMMOBILIZED KNEE
MODEL
A. Ando, Y. Hagiwara, E. Chimoto, Y. Onoda, H. Suda, E. Itoi. Tohoku
University, Sendai, JAPAN
Purpose: Joint immobilization is an essential treatment in daily exami-
nations but it also causes degeneration of the articular cartilage. Intra-
articular hyaluronan (HA) injection is widely used as a treatment of
osteoarthritis (OA) due to its physical and biological activities. Though
a large number of studies regarding chondroprotective effects of HA on
OA animal models have been reported, most of these are based on joint
instability models by resection of ligaments or meniscus. There were few
reports of the effects of HA regarding immobilized joints. In this study, we
examined the chondroprotective effects of exogenously administered HA
in a rat immobilized knee model.
Methods: Animals: A total of 84 adult male Sprague-Dawley rats weigh-
ing from 380–400 g were used. Their unilateral knee joints were immo-
bilized rigidly at 150º in ﬂexion with a plastic plate and metal screws
placed internal but extra-articularly for various periods (1, 2, 4, 6, 8,
12, and 16 weeks). 50 ml of HA (molecular weight = 1.9×106) was
administered intra-articularly for HA group on the day after surgery
and once a week until euthanasia. The same amount of saline was
administered for control group. Tissue Preparation: The specimens were
ﬁxed with 4% paraformaldehyde. After decalciﬁcation and dehydration,
the specimens were embedded in parafﬁn. The embedded tissue was
cut into 5mm sagittal sections. Standardized serial sections were created
in the medial midcondylar region of the knee. Histological Evaluation:
We chose 3 areas (non-contact, transitional, and contact area) from the
articular surface of the femur and tibia. A degree of degeneration in each
section from the 6 areas was evaluated respectively using the histological
grading scheme (modiﬁed Mankin’s score). The thickness of the total
articular cartilage was measured and the number of chondrocytes was
counted in each area, respectively.
Figure 1. Femur contact area 16 weeks.
